Tue. 27 Feb 2024, 7:07am ET
Benzinga
Earnings, News
Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.69) by 5.8 percent. This is a 51.33 percent increase over losses of $(1.50) per share from the same period last year. The company reported quarterly sales of $146.38 million which beat the analyst consensus estimate of $143.59 million by 1.94 percent. This is a 545.89 percent increase over sales of $22.66 million the same period last year.